Liquidia (LQDA) Stock: Buy, Sell, or Hold?
LQDA - Liquidia Corporation Common Stock
$38.86
2.51 (6.91%)
â˛
5d:
+14.5%
30d:
-43.39%
90d:
-56.35%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 02, 2026
10d
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Oct 13, 2026 at $35.97 · last confirmed Oct 16, 2026
Strength: 8.4/10
Get Alerted When LQDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: LQDA is fairly priced but lacks strong directional signals. At 13.9% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: LQDA is fairly priced but lacks strong directional signals. At 13.9% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$35.02
Based on 5.9% avg growth
INTRINSIC VALUE TODAY
$21.75
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: LQDA is currently trading at $38.86, which is considered fair relative to its 30-day fair value range of $27.78 to $65.82. From a valuation perspective, the stock is trading at a premium (Forward PE: 17.8) compared to its historical average (12.0). At these levels, the market is pricing in 13.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, LQDA is in a downtrend. The price is approaching resistance at $39.20. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.9% recently.
Market Sentiment: LQDA scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $54.38 (+39.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LQDA is in a downtrend. The price is approaching resistance at $39.20. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.9% recently.
Market Sentiment: LQDA scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $54.38 (+39.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$27.78 -
$65.82
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.1%
Protect Your Profits
Holding LQDA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (65/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.9%)
- BULLISH: Trading 39.9% below Wall St target ($54.38)
- NEUTRAL: Trading at premium valuation - market expects 13.9% growth which is achievable
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$27.78 -
$65.82
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$26.13
Resistance Level
$39.20
Current Trend
Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.77
Wall Street Target
$54.38
(+39.9%)
Revenue Growth (YoY)
1842.7%
Profit Margin
30.7%
Valuation Premium vs History
+13.9% premium
PE vs Historical
17.8 vs 12.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+13.9%
(market-implied from PE analysis)
1-Year Target
$44.26
(+14%)
2-Year Target
$50.41
(+30%)
3-Year Target
$57.42
(+48%)
3-Yr Target (if PE normalizes)
(PE: 18â12)
PE COMPRESSION
$38.78
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 7.9%)
$54.55
(+40%)
Base:
(SPY PE: 17.8, Growth: 7.9%)
$48.81
(+26%)
Bear:
(PE: 12.0, Growth: 7.9%)
$32.96
(-15%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (26x PE), but valuation improves significantly next year (18x PE) as earnings recover.
Trailing PE: 26.15 | Current EPS (TTM): $1.39
Bull Case
$62.91
(+62%)
Analyst growth 57.3%, PE expands to 28.8
Base Case
$57.20
(+47%)
Market implied 57.3%, PE stable at 26.2
Bear Case
$24.72
(-36%)
Severe decline -20.0%, PE contracts to 22.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 22, 2026 6:29 AM ET
Data refreshes hourly during market hours. Next update: 7:29 AM
Data refreshes hourly during market hours. Next update: 7:29 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LQDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
29 analysts |
$207 | 59 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 50 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 47 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$65 | 61 BUY |
Advanced LQDA Option Strategies
Professional options setups generated by AI based on today's LQDA price and gamma walls.